All News about Neurocrine Bioscienc
![](/next-assets/images/schema-image-default.png)
Via Benzinga
![](https://www.globenewswire.com/Content/Images/intrado.png)
![](https://www.investors.com/wp-content/uploads/2022/08/Stock-neurocrinebio-01-shutt.jpg)
![](/next-assets/images/schema-image-default.png)
Neurocrine Biosciences Earnings Preview
February 03, 2023
Via Benzinga
![](https://g.foolcdn.com/editorial/images/717332/gene-therapy.jpg)
![](https://cdn.benzinga.com/files/images/story/2023/earnings_image_94.jpeg?width=1200&height=800&fit=crop)
![](https://www.valuewalk.com/wp-content/uploads/2023/01/Rural-Healthcare-768x384.jpeg)
Five Best And Worst Performing Healthcare Stocks In January 2023
February 05, 2023
Via Talk Markets
![](/next-assets/images/schema-image-default.png)
Benzinga's Top Ratings Upgrades, Downgrades For February 3, 2023
February 03, 2023
Via Benzinga
![](https://cdn.benzinga.com/files/images/story/2023/02/03/krtx_logo_light__5ab4f4e09bf3f82a517f93702cc13b5a.png?width=1200&height=800&fit=crop)
Analyst Views Karuna Therapeutics' New Licensing Deal 'As Intriguing'
February 03, 2023
Via Benzinga
![](https://www.marketbeat.com/logos/articles/small_stock-image_75217473_S.jpg)
![](https://investorplace.com/wp-content/uploads/2020/10/cheap-stocks.jpg)
![](https://www.investors.com/wp-content/uploads/2021/08/Stock-BullPaintedRushing-adobe.jpg)
![](https://investorplace.com/wp-content/uploads/2022/10/droplet-test-tube-biotech-1600-3.jpg)
![](https://cdn.benzinga.com/files/images/story/2023/01/09/2.0-voyager-pipeline_desktop-patient-resources_circle.png?width=1200&height=800&fit=crop)
![](https://cdn.benzinga.com/files/images/story/2022/12/25/aapharma.png?width=1200&height=800&fit=crop)
![](https://www.investors.com/wp-content/uploads/2018/01/Stock-climberSilo-01-shutt.jpg)
![](https://cdn.benzinga.com/files/images/story/2022/12/07/nbix_logo_light__12134bbdd373277108445dcfedb2f189.png?width=1200&height=800&fit=crop)
![](https://cdn.benzinga.com/files/images/story/2022/11/23/screenshot_2022-11-23_at_7.14.20_pm.png?width=1200&height=800&fit=crop)
![](https://www.investors.com/wp-content/uploads/2022/11/Stock-neurologybrain-02-adobe.jpg)
![](https://cdn.benzinga.com/files/images/story/2022/movers_image_22686.jpeg?width=1200&height=800&fit=crop)
![](https://cdn.benzinga.com/files/images/story/2022/11/14/image18.jpg?width=1200&height=800&fit=crop)
![](https://www.marketbeat.com/logos/articles/small_stock-image_20038039_S.jpg)
![](https://cdn.benzinga.com/files/images/story/2022/roce_image_3479.jpeg?width=1200&height=800&fit=crop)
![](https://www.investors.com/wp-content/uploads/2022/06/Stock-jeromepowell2022-02-gov.jpg)
![](https://www.investors.com/wp-content/uploads/2022/08/Stock-neurocrinebio-01-shutt.jpg)
![](https://cdn.benzinga.com/files/images/story/2022/earnings_image_1765.png?width=1200&height=800&fit=crop)
![](https://cdn.benzinga.com/files/images/story/2022/analyst_ratings_image_27899.jpeg?width=1200&height=800&fit=crop)
Benzinga's Top Ratings Upgrades, Downgrades For October 11, 2022
October 11, 2022
Via Benzinga
![](https://cdn.benzinga.com/files/images/story/2022/earnings_image_9169.jpeg?width=1200&height=800&fit=crop)
![](https://g.foolcdn.com/editorial/images/704064/scientists-in-a-lab.jpg)
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.